ADMA Biologics Inc

ADMA Healthcare Biotechnology

ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.

Revenue
+5.12%
EPS
+48.7%
Free cash flow
+1,709.5%
Total debt
+148.4%

Quarter to September 2026, against a year earlier

12.80 0.41 −3.10%
Market cap
$3.0B
P/E
16.1×
Fwd P/E
14.0×
Dividend yield
—
F-score
5/9
Altman Z
19.98
Beneish M
−0.17
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Piotroski F-Score

+8 more TTM periods

5 4 5 4
ROE
35.56% 43.30% 41.90% 41.95%
ROA
26.40% 28.13% 27.19% 28.04%
ROIC
25.69% 29.70% 29.78% 29.48%
Return on Tangible Assets
31.80% 32.90% 32.55% 33.33%
Average Days of Receivables
113.35 97.26 98.49 118.98
Free Cash Flow per Share
0.12 0.48 0.51 0.59
Free Cash Flow
27.51 112.55 116.22 132.60
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026